secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001437749-26-001048
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%
--------------------------------------------------------------------------------

- Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.
- Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.
- OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).
- CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.
- Full financial results to be reported in March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/0001437749-26-001048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926001048/apyx20260108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer